A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension

Thomas M. Cascino, Sandeep Sahay, Victor M. Moles, Vallerie V. McLaughlin

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Despite increasing therapeutic options and evolving treatment strategies, including targeting 3 therapeutic pathways, in the management of pulmonary arterial hypertension (PAH), morbidity and mortality have remained unacceptably high. Sotatercept is a first-in-class, novel activin signaling inhibitor approved for treating PAH based on evolving efficacy and safety evidence. This state-of-the-art review summarizes the current understanding of the mechanism of action, the impact on outcomes that improve how patients feel, function, and survive, and the safety and adverse event profile to inform readers of this breakthrough novel therapy.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalJournal of Heart and Lung Transplantation
Volume44
Issue number1
DOIs
StatePublished - Jan 2025

Keywords

  • outcomes
  • pulmonary arterial hypertension
  • sotatercept
  • survival
  • treatment
  • Recombinant Fusion Proteins/therapeutic use
  • Humans
  • Pulmonary Arterial Hypertension/drug therapy
  • Treatment Outcome
  • Activin Receptors, Type II/therapeutic use

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Fingerprint

Dive into the research topics of 'A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this